Table 2 Univariate and multivariate analyses of disease-free and overall survivals in 114 ER-positive breast cancer patients.

From: PSPC1 is a potential prognostic marker for hormone-dependent breast cancer patients and modulates RNA processing of ESR1 and SCFD2

Variable

Univariate

Multivariate

P value

P value

Relative risk (95% CI)

Disease-free survival

PSPC1 (weak/strong)

0.0010†

0.011

3.9 (1.4–11.3)

pN (N0,1/N2)

0.0021†

0.049

2.9 (1.0–8.5)

pT (pT1/pT2–4)

0.0077†

0.053

3.2 (1.0–10.1)

SCFD2 (weak/strong)

0.033†

0.083

2.6 (0.9–7.4)

PR (negative/positive)

0.24

  

HER2 status (negative/positive)

0.44

  

PSF (weak/strong)

0.49

  

Histological grade

0.51

  

Overall survival

PSPC1 (weak/strong)

0.0079†

0.0053

10.5 (2.0–54.5)

pN (N0,1 /N2)

0.0093†

0.0053

8.3 (1.9–37.1)

SCFD2 (weak/strong)

0.021†

0.075

4.4 (0.9–22.2)

PSF (weak/strong)

0.035†

0.031

10.8 (1.3–93.5)

PR (negative/positive)

0.56

  

pT (pT1/pT2–4)

0.17

  

HER2 status (negative/positive)

0.20

  

Histological grade

0.79

  
  1. Statistical analysis was evaluated by a proportional hazard model (Cox).
  2. P value < 0.05 and 0.05 ≤ P value < 0.10 were considered significant and borderline significant, and were listed in bold and italic, respectively.
  3. 95% CI 95% confidence interval.
  4. †Significant (P < 0.05) values were examined in the multivariate analyses in this study.
Back to article page